Additional file 8 of Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial

Supplementary Material 8: Appendix 8: Definitions of adverse events. Definitions of adverse events used during FEDORA.

Institutions

Publication Details

Journal
Figshare
Published
2025-01-01
DOI
https://doi.org/10.6084/m9.figshare.28180953.v1
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Additional file 8 of Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial

Figshare
Myeloproliferative Neoplasms: Diagnosis and Treatment
article

Additional file 8 of Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial

article en

Abstract

Supplementary Material 8: Appendix 8: Definitions of adverse events. Definitions of adverse events used during FEDORA.

Figshare
National Health Service (GB), Queen's University Belfast (GB), University of Oxford (GB), University of Birmingham (GB)
Zero hunger
Openalex Percentile: Top 37%
Myeloproliferative Neoplasms: Diagnosis and Treatment
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Additional file 8 of Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial · Figshare (2025) | TGRS Research Map | TGRS